Literature DB >> 1054729

Response to influenza vaccine in adjuvant 65-4.

J W Smith, W B Fletcher, M Peters, M Westwood, F J Perkins.   

Abstract

A comparison was made of the antibody response and subjective reactions to zonally-purified influenza vaccine in aqueous suspension and in peanut oil adjuvant 65-4. Both preparations contained 700 CCA units of A/Aichi/2/68, and 300 CCA units of B/Mass/1/71. Subjective reactions were recorded by asking the volunteers to complete a record daily for 5 days. Pain at the injection site was recorded by 64 per cent of the recipients of the oil adjuvant vaccine compared with 35 per cent of the aqueous recipients, but local redness was more frequent after aqueous vaccine. Systemic symptoms was recorded a little more frequently after aqueous than oil adjuvant vaccine. When measured 71/2 weeks after a single dose of vaccine, the HAI geometric mean antibody titre (G.M.T) to the A/Hong Kong/1/68 antigen (antigenically similar to the A/Aichi/2/68 antigen in the vaccine) increased 2-7 fold after aqueous and 16-4 fold after adjuvant vaccine. Sixty-two weeks after vaccination the antibody titres remained higher in those given adjuvant vaccine. The G.M.T. to B/Mass/1/71 increased 1-9 fold 71/2 weeks after aqueous vaccine and 3-7 fold after adjuvant vaccine. The antibody response to both influenza A and B antigens was broader in the recipients of adjuvant vaccine. The G.M.T. to A/England/42/72 increased 2-8-fold after aqueous and 13-fold after adjuvant vaccine; and to B/England/847/73 it increased 1-3-fold after aqueous and 1-9-fold after adjuvant vaccine.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1054729      PMCID: PMC2130368          DOI: 10.1017/s0022172400024323

Source DB:  PubMed          Journal:  J Hyg (Lond)        ISSN: 0022-1724


  7 in total

1.  The role of serum haemagglutination-inhibiting antibody in protection against challenge infection with influenza A2 and B viruses.

Authors:  D Hobson; R L Curry; A S Beare; A Ward-Gardner
Journal:  J Hyg (Lond)       Date:  1972-12

2.  Long-term mortality follow-up of Army recruits who received adjuvant influenza virus vaccine in 1951-1953.

Authors:  G W Beebe; A H Simon; S Vivona
Journal:  Am J Epidemiol       Date:  1972-04       Impact factor: 4.897

3.  Immunization against influenza: rationale and recommendations.

Authors:  T C Eickhoff
Journal:  J Infect Dis       Date:  1971-04       Impact factor: 5.226

Review 4.  Critical appraisal of emulsified oil adjuvants applied to viral vaccines.

Authors:  M R Hilleman
Journal:  Prog Med Virol       Date:  1966

5.  NEW METABOLIZABLE IMMUNOLOGIC ADJUVANT FOR HUMAN USE. 3. EFFICACY AND TOXICITY STUDIES IN MAN.

Authors:  J STOKES; R E WEIBEL; M E DRAKE; A F WOODHOUR; M R HILLEMAN
Journal:  N Engl J Med       Date:  1964-09-03       Impact factor: 91.245

6.  Prevalence of antibody to current influenza viruses and effect of vaccination on antibody response.

Authors:  M S Pereira; P Chakraverty; G C Schild; M T Coleman; W R Dowdle
Journal:  Br Med J       Date:  1972-12-23

7.  Adjuvant influenza vaccines.

Authors:  C H Stuart-Harris
Journal:  Bull World Health Organ       Date:  1969       Impact factor: 9.408

  7 in total
  2 in total

1.  A novel retinoic acid, catechin hydrate and mustard oil-based emulsion for enhanced cytokine and antibody responses against multiple strains of HIV-1 following mucosal and systemic vaccinations.

Authors:  Mingke Yu; Michael Vajdy
Journal:  Vaccine       Date:  2011-01-25       Impact factor: 3.641

2.  The response to inactivated influenza A (H3N2) vaccines: the development and effect of antibodies to the surface antigens.

Authors:  A F Smith; J R Davies
Journal:  J Hyg (Lond)       Date:  1977-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.